Vericiguat: A New Horizon for Heart Failure Treatment

Despite advances in guideline-directed medical therapy (GDMT), heart failure with reduced ejection fraction (HFrEF) remains a progressive condition with high morbidity and mortality. Vericiguat, a soluble guanylate cyclase (sGC) stimulator, represents a novel therapeutic class that augments the nitric oxide–sGC–cyclic guanosine monophosphate (cGMP) pathway, which is impaired in HFrEF. The VICTORIA trial demonstrated that vericiguat significantly reduced the composite endpoint of cardiovascular death or heart failure hospitalization (HFH) in high-risk patients following a worsening event. Recent data from the VICTOR trial and subsequent pooled analyses suggest broader applicability, indicating that vericiguat may signal a potential mortality benefit in selected stable, ambulatory HFrEF patients with elevated natriuretic peptides but without recent hospitalization. The safety profile is favorable, with hypotension being the most common adverse event. Overall, vericiguat offers a valuable therapeutic option for a wide spectrum of HFrEF patients. Moreover, the ability of vericiguat to improve outcomes in both post-worsening and selected high-risk stable populations suggests this sGC stimulator may serve as a critical fifth component of GDMT, offering a new avenue for a personalized approach to HFrEF treatment. This review synthesizes key clinical evidence to elucidate the role of vericiguat in modern HFrEF management.